Wall Street funds back China’s WuXi AppTec as weight-loss drug orders soar

US global asset managers, including BlackRock, have expanded stakes in mainland Chinese pharmaceutical contractor WuXi AppTec over the past two months, betting that a surge in weight-loss drug manufacturing orders will lift earnings in the first half of the year.
Global investors were increasingly interested in China’s contract development and manufacturing organisation, and biotechnology sector, said Linda Shu, head of China healthcare research at HSBC.
“WuXi Apptec is heavily owned given its...